ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma
Authors
Keywords
-
Journal
ACTA PHARMACOLOGICA SINICA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-15
DOI
10.1038/s41401-020-0439-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- To eat or not to eat — the metabolic flavor of ferroptosis
- (2018) Minghui Gao et al. CURRENT OPINION IN CELL BIOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
- (2018) Giorgia Marisi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
- (2017) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis
- (2017) Ping Wang et al. Expert Review of Gastroenterology & Hepatology
- Identification of ACSL4 as a biomarker and contributor of ferroptosis
- (2016) Hua Yuan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis
- (2016) Xiaofang Sun et al. HEPATOLOGY
- Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib
- (2016) Aline Houessinon et al. Molecular Cancer
- Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis
- (2016) Valerian E Kagan et al. Nature Chemical Biology
- ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition
- (2016) Sebastian Doll et al. Nature Chemical Biology
- Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
- (2016) Omar Abdel-Rahman et al. Expert Review of Gastroenterology & Hepatology
- Effect of pioglitazone medication on the incidence of dementia
- (2015) Michael T. Heneka et al. ANNALS OF NEUROLOGY
- The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells
- (2015) Christophe Louandre et al. CANCER LETTERS
- CCAAT/enhancer binding protein α predicts poorer prognosis and prevents energy starvation-induced cell death in hepatocellular carcinoma
- (2015) Guo-Dong Lu et al. HEPATOLOGY
- Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells
- (2015) Xiaofang Sun et al. HEPATOLOGY
- Regulation of Ferroptotic Cancer Cell Death by GPX4
- (2014) Wan Seok Yang et al. CELL
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
- (2014) Arnoud J. Templeton et al. JNCI-Journal of the National Cancer Institute
- Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2014) Leonardo Gomes da Fonseca et al. MEDICAL ONCOLOGY
- Pharmacological inhibition of cystine–glutamate exchange induces endoplasmic reticulum stress and ferroptosis
- (2014) Scott J Dixon et al. eLife
- Activation of lysosomal function in the course of autophagy via mTORC1 suppression and autophagosome-lysosome fusion
- (2013) Jing Zhou et al. CELL RESEARCH
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib
- (2013) Christophe Louandre et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
- (2013) Nicola Personeni et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma
- (2013) Jie Sheng Chu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma
- (2012) Nicola Personeni et al. JOURNAL OF HEPATOLOGY
- NIH Image to ImageJ: 25 years of image analysis
- (2012) Caroline A Schneider et al. NATURE METHODS
- Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy
- (2011) Massimo Iavarone et al. HEPATOLOGY
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- C/EBPα Is Up-regulated in a Subset of Hepatocellular Carcinomas and Plays a Role in Cell Growth and Proliferation
- (2010) Guo–Dong Lu et al. GASTROENTEROLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. JNCI-Journal of the National Cancer Institute
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started